These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34510475)

  • 1. How do I… facilitate a rapid response to a public health emergency requiring plasma collection with a public-private partnership?
    Miller MJ; Skrzekut A; Kracalik I; Jones JM; Lofy KH; Konkle BA; Haley NR; Duvenhage M; Bonnett T; Holbrook M; Higgs E; Basavaraju SV; Paranjape S
    Transfusion; 2021 Oct; 61(10):2814-2824. PubMed ID: 34510475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
    Boonyaratanakornkit J; Morishima C; Selke S; Zamora D; McGuffin S; Shapiro AE; Campbell VL; McClurkan CL; Jing L; Gross R; Liang J; Postnikova E; Mazur S; Lukin VV; Chaudhary A; Das MK; Fink SL; Bryan A; Greninger AL; Jerome KR; Holbrook MR; Gernsheimer TB; Wener MH; Wald A; Koelle DM
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33320842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.
    Goodhue Meyer E; Simmons G; Grebe E; Gannett M; Franz S; Darst O; Di Germanio C; Stone M; Contestable P; Prichard A; Reik R; Vassallo R; Young P; Busch MP; Williamson P; Dumont LJ
    Transfusion; 2021 Apr; 61(4):1160-1170. PubMed ID: 33554362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.
    Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P
    Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
    Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation.
    Schmidt AE; Vogel P; Chastain CA; Barnes T; Roth NJ; Simon TL
    J Clin Apher; 2022 Oct; 37(5):449-459. PubMed ID: 35815776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
    Karbiener M; Farcet MR; Ilk R; Schreiner J; Lenart J; Powers N; Stewart JM; Tallman H; Kreil TR
    Transfusion; 2021 Apr; 61(4):1141-1147. PubMed ID: 33615484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
    Balcerek J; Trejo E; Levine K; Couey P; Kornberg ZV; Rogine C; Young C; Li PJ; Shy BR; Taylor JE; Bakhtary S; Friedlander T; Lynch KL; Bern C; Esensten JH
    Am J Clin Pathol; 2021 Mar; 155(4):515-521. PubMed ID: 33399201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial.
    Romera Martínez I; Avendaño-Solá C; Villegas Da Ros C; Bosch Llobet A; García Erce JA; González Fraile MI; Guerra Domínguez L; Vicuña Andrés I; Anguita Velasco J; González Rodríguez VP; Contreras E; Urcelay Uranga S; Pajares Herraiz ÁL; Jimenez-Marco T; Ojea Pérez AM; Arroyo Rodríguez JL; Pérez-Olmeda M; Ramos-Martínez A; Velasco-Iglesias A; Bueno Cabrera JL; Duarte RF
    Vox Sang; 2024 Jan; 119(1):27-33. PubMed ID: 37986640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
    Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
    Front Immunol; 2021; 12():739037. PubMed ID: 34594341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
    Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
    Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
    Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
    Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda.
    Muttamba W; Lusiba J; Namakula LO; Byakika-Kibwika P; Ssali F; Ddungu H; Mugenyi L; Kiwanuka N; Sekibira R; Kityo C; Keyune D; Acana S; Musinguzi A; Masasi A; Byamugisha J; Mpanju D; Musoki WJ; Tukamuhebwa HA; Nakwagala F; Bagaya BS; Kayongo A; Kimuli I; Nantanda R; Katagira W; Buregyeya E; Byanyima R; Byarugaba B; Siddharthan T; Mwebesa H; Charles O; Joloba ML; Bazeyo W; Kirenga B
    PLoS One; 2021; 16(6):e0252306. PubMed ID: 34138909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
    Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
    Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.